Deferasirox nephrotoxicity-the knowns and unknowns

Area of Science:

• Nephrology
• Pharmacology
• Toxicology

Background:

• Deferasirox is an FDA-approved oral iron chelator for transfusion-related iron overload.
• Nephrotoxicity, manifesting as decreased glomerular filtration rate (GFR) and proximal tubular dysfunction, is a significant adverse effect.
• Existing data on deferasirox nephrotoxicity mechanisms and risk factors are limited.

Purpose of the Study:

• To review the incidence and characteristics of deferasirox-induced nephrotoxicity.
• To highlight the need for further research into the molecular mechanisms of this adverse effect.
• To emphasize the importance of monitoring and investigating deferasirox use in specific populations, such as the elderly.

Main Methods:

• Review of clinical trials and observational studies on deferasirox treatment.
• Analysis of reported cases of nephrotoxicity.
• Discussion of potential molecular pathways and risk factors.

Main Results:

• GFR decrease is reported in 30-100% of patients, varying by dose and assessment method.
• Nephrotoxicity is often nonprogressive or reversible, with rapid iron depletion as a risk factor.
• Deferasirox induces apoptosis in cultured proximal tubular cells, but the trigger remains unclear.

Conclusions:

• Deferasirox-induced nephrotoxicity is a common concern requiring careful monitoring.
• Further research is essential to elucidate molecular mechanisms and optimize patient management.
• Special attention should be given to elderly patients due to potential increased susceptibility.